Test Price
2,800 AED✅ Home Collection Available
AIP Gene Germline Mutation Analysis (NGS) for ACTH-Secreting Pituitary Adenoma in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Precision Genetics for Hereditary Pituitary Adenoma Risk Stratification
- Analytical Sensitivity: >99.9% across coding exons and splice junctions via ISO 9001:2015 validated NGS workflow.
- Premium Logistics: VIP mobile phlebotomy & temperature-controlled cold-chain home collection available daily 8 AM – 11 PM.
- Post-Test Clinical Support: Complimentary telephone consultation with a DHA-licensed Consultant Medical Geneticist to interpret results and guide management.
- Insurance Verification: Direct coverage check via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This next-generation sequencing (NGS) assay interrogates the full coding region and splice-site boundaries of the AIP gene to detect pathogenic germline variants associated with familial isolated pituitary adenoma, specifically ACTH-secreting adenomas that drive Cushing's disease. The test employs hybridisation capture-based enrichment followed by Illumina sequencing with bioinformatic variant calling and interpretation according to ACMG/AMP guidelines.
| Feature | DNA Labs UAE – AIP NGS | Alternative – Sanger Sequencing (AIP) |
|---|---|---|
| Coverage & Sensitivity | Complete coding exons + 20 bp flanking introns; >99.9% analytical sensitivity for SNVs and indels | Single-exon or targeted amplicons; may miss deep intronic, regulatory, or structural variants |
| Method | Next-Generation Sequencing (NGS) with dual-direction bioinformatic pipeline & orthogonal confirmation | Sanger capillary electrophoresis; lower throughput, limited multiplexing |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Regulatory Compliance | DHA/MOHAP licensed; ISO 9001:2015 certified; PDPL compliant | May lack local accreditation & data protection safeguards |
Physician Insight & Safety Protocols
Clinical Commentary from Our Genetics Specialist
"A positive AIP germline mutation result indicates a hereditary predisposition to pituitary adenoma, not an active cancer diagnosis. This finding warrants multidisciplinary evaluation — endocrinology, genetics, and neuroradiology — to establish a baseline and surveillance plan. Cascade testing of at-risk relatives is essential for early detection. Patients must continue all prescribed medications; no therapeutic changes should be made without direct specialist consultation."
— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Medication Advisory & Pretreatment Requirements
Do not discontinue or alter any prescribed medication — including glucocorticoid replacement or antihypertensives — without explicit instruction from your treating physician. This genetic test result alone does not dictate therapy changes.
Safety Exclusion Criteria & Clinical Red Flags
- Pregnancy: Invasive phlebotomy requires obstetric clearance if clinically indicated.
- Acute Psychiatric Crisis: Genetic counselling should be deferred until the patient is clinically stable.
- Minors: Parental consent and a mandatory genetic counselling session are required per UAE paediatric care standards.
- Emergency Red Flags: Sudden severe headache, visual field loss, or symptoms of pituitary apoplexy warrant immediate emergency care — not this test.
Patient FAQ & Clinical Guidance
1. What does the AIP gene test detect, and who should consider it?
The AIP germline mutation analysis identifies inherited DNA variants that predispose to familial isolated pituitary adenoma, particularly ACTH-secreting tumours responsible for Cushing's disease. This test is indicated for individuals with early-onset pituitary adenoma (<30 years), a family history of pituitary or endocrine tumours, or clinical features suggestive of a genetic syndrome. It guides lifelong endocrine surveillance, family cascade screening, and personalised management planning.
2. How is the sample collected, and what preparation is needed?
A standard peripheral whole blood sample (5–10 mL in EDTA) is collected. An 8-hour fast is recommended for consistency with concurrent metabolic panels. A mandatory pre-test genetic counselling session is conducted to document a three-generation pedigree, confirm informed consent, and discuss implications of all possible results. Please inform our team about any anticoagulant or antiplatelet medications.
3. What are the clinical implications of a positive result, and does UAE insurance cover this test?
A pathogenic AIP variant indicates a hereditary predisposition requiring annual endocrine assessment (ACTH, cortisol, prolactin, IGF-1) and pituitary MRI every 1–2 years. Proactive surveillance enables early detection and intervention before symptomatic progression. Most UAE health insurance plans cover this test when medically justified by an endocrinologist or geneticist; we verify your coverage directly via WhatsApp +971 54 548 8731.
4. How are results reported, and will I receive genetic counselling?
Results are delivered as a comprehensive clinical report within 3–4 weeks, detailing each identified variant with ACMG/AMP pathogenicity classification, population frequency data, and clinical interpretation. Every patient receives a complimentary telephone consultation with our Consultant Medical Geneticist — Lina Osama Zaki Quteineh (DHA 9294403) — to explain the findings, discuss surveillance recommendations, and coordinate family testing if indicated.
UAE Regulatory & Data Privacy Adherence
Our services operate in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, and Federal Decree-Law No. 4 of 2016 on Medical Liability. Patient genetic data is encrypted, access-controlled, and stored within UAE-based secure servers. The facility holds DHA/MOHAP license 1143 with ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139), guaranteeing data integrity, clinical excellence, and adherence to international standards for genetic testing.
Clinical & Logistical Metadata
| Test Name | AIP Gene Germline Mutation Analysis (NGS) for ACTH-Secreting Pituitary Adenoma |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 weeks |
| Sample Type / Matrix | Peripheral Whole Blood (5–10 mL EDTA) — VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM – 11 PM |
| Methodology Used | Next-Generation Sequencing (NGS) – Hybridisation capture, Illumina platform, bioinformatic variant interpretation per ACMG/AMP |
| ICD-10-CM Code | E24.0 (Pituitary-dependent Cushing's disease) |
| LOINC Code | 81247-1 (AIP gene mutation analysis in Blood) |
| DHA Facility License & Laboratory Address | License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians